Où achat cialis sans ordonnance et acheter viagra en France.
ImmusanT Names Ferdinand E. Massari as Chief Medical Officer
CAMBRIDGE, Mass., September 9, 2013
– ImmusanT announced today that Ferdinand E.
Massari, MD has joined the biopharmaceutical company as Senior Vice President, Development
and Chief Medical Officer. Dr. Massari will oversee the clinical development program for the
therapeutic vaccine Nexvax2® for celiac disease and its companion diagnostic, as well as future
development programs for other autoimmune diseases.
“Ferdinand will be a valuable contributor to ImmusanT with his diverse expertise in drug
development and immunology. He will help shape and drive the clinical development of
Nexvax2, a disease-modifying treatment, and our companion diagnostic for celiac disease
patients in search of an alternative to a gluten free diet,” commented Leslie Wil iams, President
and CEO of ImmusanT.
“By joining the ImmusanT team, I have the opportunity and privilege to make a significant
impact on a community of patients whose only option is a gluten free diet,” commented Dr.
Massari. “I look forward to helping advance the clinical development of Nexvax2 to an even
broader, international patient population.”
Dr. Massari has over 20 years of experience in all stages of drug development and comes to
ImmusanT having most recently served as a consultant providing product candidate evaluation
and clinical plan development services to companies and investors. Previously, Dr. Massari was
Global Head and Vice President of Clinical and Medical Affairs at Shire Human Genetic
Therapies, where he was responsible for the oversight of global development of products to
treat rare genetic disorders. Earlier, Dr. Massari served as Senior Vice President of Drug
Development and Chief Medical Officer at Coley Pharmaceutical Group where he oversaw the
development of novel therapeutics for hepatitis C infection and lupus. Dr. Massari has held
executive positions at Pfizer where he led clinical programs for ZYVOX (linezolid), one of the
most successful hospital antibiotics to date. He began his career at Merck where he was its first
HIV-trained physician-scientist and served as Director, Clinical Research, Infectious Disease.
Dr. Massari is board certified in internal medicine and trained in allergy and immunology in the
Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases,
National Institutes of Health. Dr. Massari obtained his M.D. from the Jefferson Medical College
in Philadelphia, PA, and his B.A. in political science with a pre-med concentration from the
University of Maryland.
About ImmusanT, Inc.
ImmusanT is a privately-held biotechnology company focused on restoring tolerance to gluten in
celiac disease by harnessing new discoveries in immunology that aim to improve diagnosis and
treatment and return patients to a normal diet, good health and improved quality of life. The
company is developing a therapeutic vaccine for celiac disease, and a companion
diagnostic and monitoring tool to improve celiac disease management. ImmusanT's targeted
immunotherapy discovery platform can be applied to a variety of epitope-specific autoimmune diseases. Founded in 2010, ImmusanT is backed by Vatera Healthcare Partners. More information can be found ator follow Immusan
ImmusanT Contact: Leslie J. Williams, President & CEO (617) 299-8399 x 201 Leslie@ImmusanT.com Media Contact: Canale Communications Pam Lord (619) 849-6003 firstname.lastname@example.org
MANAGEMENT A Practical Guide for Clinicians FIFTH EDITION Chapter 20: New Concepts in Back Pain Management: Decompression, Reduction, and Stabilization C. Norman Shealy, M.D., Ph.D., FA.C.S. Pierre L. Leroy, M.D., F.A.C.S. C Norman Shealy, M.D., Ph.D., F.A.CS. Pierre L. LeRoy, M.D., F.A.CS. ABSTRACT A thorough evaluation of previous traction techniques reveals no consistent
Programma – Misselijkheid en braken in de palliatieve zorg Misselijkheid en braken in de palliatieve zorg A1 Definitie, ontstaan van misselijkheid en braken A2 Diagnostiek van misselijkheid in palliatieve fase A3 Niet-medicamenteuze en medicamenteuze behandeling Gastro-intestinale obstructie (ileus) B4 Behandeling van een hoge gastro-intestinale obstructie Actie en verantwoord